SCHEMBL5535949

SCHEMBL5535949

CCOc1ccc2[c]csc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
ALDH1A1 P00352 5/20 0.51
HSD17B10 Q99714 4/20 0.51
PSMB8 P28062 1/20 0.44
NQO1 P15559 1/20 0.43
KMT2A Q03164 4/20 0.43
TP53 P04637 3/20 0.43
CYP3A4 P08684 3/20 0.43
TSHR P16473 2/20 0.43
LMNA P02545 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
KDM4E B2RXH2 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA3 P07451 1/20 0.38
PKM P14618 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9624277 0.87 MAPT (0.40) MAPTALDH1A1HSD17B10KMT2ALMNA
SCHEMBL5535945 0.86 ALDH1A1 (0.44) MAPTALDH1A1HSD17B10PSMB8NQO1
SCHEMBL9624777 0.81 HSD17B10 (0.52) MAPTALDH1A1HSD17B10TP53CYP3A4
SCHEMBL9624839 0.77 ALDH1A1 (0.42) MAPTALDH1A1HSD17B10KMT2ACYP3A4
SCHEMBL9624426 0.73 CA2 (0.42) ALDH1A1KDM4ECA12CA2CA5A
SCHEMBL5541830 0.73 NPC1 (0.39) MAPTALDH1A1KMT2ALMNAMEN1
SCHEMBL5534587 0.72 NPC1 (0.43) MAPTHSD17B10TP53CYP3A4LMNA
SCHEMBL210265 0.70 MAPT (0.33) MAPTALDH1A1HSD17B10KMT2ATP53
SCHEMBL2885650 0.69 NQO1 (0.48) MAPTALDH1A1HSD17B10PSMB8NQO1
SCHEMBL5544027 0.69 ALDH1A1 (0.69) MAPTALDH1A1HSD17B10PSMB8NQO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-5175157-A Cardiovascular disorders BOEHRINGER INGELHEIM GMBH (DE) 1992-12-29 US disclosed
US-5116986-A HETEROAROMATIC AMINE DERIVATIVES DR. KARL THOMAE GMBH (DE) 1992-05-26 US disclosed
US-4912115-A Cardiovascular disorders DR. KARL THOMAE GMBH (DE) 1990-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885ALDH1A1 355/4885HSD17B10 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.